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Commercialization Considerations for Individualized
Diagnostic and Drug Therapies Resulting from
Pharmacogenomics
Jefifrey L. Moe °
Imagine I go onto the Internet, order a home test for the most
common gene variations, or "alleles," associated with commonly
prescribed prescription drugs. I swab the inside of my mouth and
send it back to the lab. Weeks later, I receive what looks like a
credit card. This card is actually a CD-ROM, holding information
about approximately 50-100 drugs that I may metabolize in an
idiosyncratic manner, therefore requiring, for my unique response,
different product information ("PI") about dosing and risks
associated with that drug. The CD-ROM will also give me
information about many over-the-counter preparations and how my
body may process them differently. Perhaps, it may also require
different dosing and safety information than what has been
approved and printed on the product.
This scenario reflects the fact that we now have the
pharmacogenomic technology to identify individual gene variation
associated with drug receptors, drug transport mechanisms, and
drug-metabolizing enzymes which affect individual drug
response.1 The potential of individualized drug therapy raises a
number of questions for manufacturers ("How do we provide
individualized drug response information?"), for care providers
("How do I interpret individualized versus population-based
information? Do I need this new genome-based information or do
I have other available clinical information to gauge individual
differences in drug response?"), for patients ("Do I want
individualized information? How much will I pay for this
information? What benefits will I gain and can I understand this
information? Are there risks to me if others discover this
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information about me as an individual?"), for regulators ("Should
we require this information be provided by manufacturers and
make it available to patients and care providers? Should we
require some diagnostic tests be administered before a drug is
administered to improve patient safety?"), and for reimbursers
("Should our benefits design include coverage for
pharmacogenomic-based diagnostics and individualized drug
therapies?"). As these five stakeholders respond to these and other
questions we will see the potential of phamacogenomics shaped by
the market realities of commercialization. We can look to
historical examples of market responses to innovation to gain some
insight into the future for pharmacogenomics. Of course this
innovative new technology will not simply replicate the history of
earlier innovations. It will have its own course which we cannot
perfectly predict.
For each gene, there is a pair of copies, known as alleles.2
Over many generations, variant alleles have emerged.3 When
these occur in the general population at a rate greater than one
percent, they are deemed single nucleotide polymorphisms
("SNPs ).4 When we find these variants in the individual, we are
able to look at transport mechanisms, metabolism, absorption,
toxicity, generally how individuals differ in drug response. In the
clinical trial context for developing new drugs, patient sub-
populations can be created where they share certain genetic
profiles which can show drug responses that are safer or more
efficacious. We speak of these genetic differences regarding drugs
in two general ways-pharmacogenomics 5 and pharmacokinetics.
6
2. See Genome Glossary, http://www.oml.gov/sci/techresources/Human_
Genome/glossary/glossary.shtml (last visited Nov. 2, 2005).
3. For basic information about the human genome, visit the Internet site of
the National Human Genome Research Institute (NHGRI), http://www.nhgri
.nih.gov.
4. See SNP Fact Sheet, http://www.oml.gov/sci/techresources/Human
Genome/faq/snps.shtml (last visited Nov. 2, 2005); SNPs: Variations on a
Theme, http://www.ncbi.nlm.nih.gov/About/primer/snps.html (last visited Nov.
2, 2005).
5. See Virna Ignacio Alumete, Drug Therapy and Pharmacogenomics
(2000), http://www.medscape.com/viewarticle/419158; National Center for
Biotechnology Information, Pharmacogenomics Factsheet, One Size Does Not
Fit All: The Promise of Pharmacogenomics, http://www.ncbi.nlm.nih.gov/
About/primer/pharm.html (last visited Nov. 2, 2005).
6. For general information about pharmacokinetics and
pharmacogenomics, see Food and Drug Administration, http://www.fda.gov
(last visited Nov. 2, 2005); ALS Therapy Development Foundation glossary,
http://www.als.net/resources/glossary.asp (last visited Nov. 2, 2005); and
Environmental Health Center glossary, http://www.nsc.org/ehc/glossarl.htm
(last visited Nov. 2, 2005).
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The first involves screening candidates based upon the presence of
a genotytge marker,7 while the second centers on metabolizing
activities.
Two pharmacokinetic applications that come to mind include
individualized patient differences in response to Warfarin, a drug
used to stop blot clots from forming and growing larger, and
mercaptopurine (6MP), a drug used in the treatment of acute
lymphoblastic leukemia-a childhood leukemia. One study on
Warfarin was conducted with about 185 patients who had two
variant alleles. 9 The study compared the two variant allele sub-
populations and asked, "Do they, in fact, have differing
anticoagulation conditions? Do they differ in their response to
drug treatment and does following the recommended dosing lead
to safety concerns? Do they have serious or even life-threatening
bleeding when their unique drug response, in effect, causes them to
be under-medicated and therefore at greater risk of uncontrolled
bleeding?"
Of these patients, there were two that had a life-threatening
occurrence resulting from their genetic variation and resulting drug
response.' 0  This was a statistically significant finding which
triggered questions such as, "Should all patients be tested to
determine their individualized drug response?" and "How much
risk, measured in cost and adjustments to life years, does this
unique response create and how much additional cost is the
diagnostic for the benefit of adverse drug response costs compared
with those that could be avoided?" The opportunity to use
innovative gene-based diagnostics is available to us. But as
payers, patients, and providers we are quickly led to questions like
these about the cost-effectiveness of these new therapies. And we
have very little experience, and therefore very little data, upon
which to make these calculations and these judgments. The history
of the uptake of innovation in medicine tells us that the lack of
cost-effectiveness studies or severely limited data will not
necessarily impede adoption. If the past is prologue, that history
also tells us that there will likely be predictable requirements for
gene-based diagnostics and therapies to become widely used.
Ultimately, cost-effectiveness will have to be established if there is
to be sustained, long-term use of these new therapies. But in the
7. See sources cited supra note 5.
8. See sources cited supra note 6.
9. See generally Mitchell K. Higashi et al., Association Between CYP2C9
Genetic Variants and Anticoagulation-Related Outcomes During Warfarin
Therapy, 287 J. Am. Med. Ass'n. 1613, 1690-98 (2002).
10. Id. at 1695.
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short run, when we're establishing a market and commercializing,
it's almost certain that we won't know if individualized therapy
really avoids, or improves, total costs and improves patient
outcomes in a measurable way. Markets and commercialization in
medicine frequently occur in the absence of a real understanding of
cost information. The U.S. market, in particular, has a built in pro-
innovation bias to allow new technologies to gain market access
first.
Let us take, for example, mercaptopurine (6MP) where one
could argue the right constellation of forces were aligned to
suggest wide-spread adoption of a gene-based diagnostic test to
individualize 6MP therapy. Those factors were: 1) a life-
threatening outcome and high overall costs of treatment, 2)
treatment by a small sub-specialty of care providers, 3) good
association of the gene variation with clinical differences, and 4) a
reliable and "affordable"-as considered in the context of the
overall costs of treatment and patient outcomes from the disease-
diagnostic." I  It suggested to many that mandatory diagnostic
testing before the commencement of mercaptopurine therapy made
sense and was something the FDA was considering. However, as
discussed in Dr. Woodcock's presentation, physicians were,
unexpectedly, opposed to mandatory diagnostic testing. 12 They
argued that other clinical markers were typically monitored and,
therefore, they should not be required to use the diagnostic. This
suggests a fifth factor which may influence commercialization: the
prevalence of other clinical markers to monitor individualized
differences in drug response. The care provider may not need to
know the actual gene variation responsible for differences in drug
response to adequately protect the patient and avoid creating
significant, unnecessary treatment costs.
There are other barriers or concerns for practitioners in the
application of pharmacogenomics in clinical practice. While an
advantage of pharmacogenomics is to potentially reduce the
number of patients required in clinical trials while improving their
responses to the new therapy, these advantages also have a
downside. Limiting the number of patients in trials exacerbates the
limited knowledge clinicians have as a new therapy is launched.
Moreover, if we consider the additional concern that has been
11. With some cancer pharmaceutical therapies having ex-factory prices in
the $ 10,000's per year, a diagnostic costing less than $1000, which holds out the
promise of making the therapy more effective, is likely to be viewed by many
patients as "affordable" even if that cost is not insurance reimbursable.
12. Janet Woodcock, FDA Policy on Pharmacogenomic Data in Drug
Development, 66 La. L. Rev. (Special Issue) 91, 93, 95, 101 (2006).
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raised-that women and minorities have been under-represented in
clinical trials-we find that the promise of this new technology
also will allow, under the current clinical trials and approval
regime, a drug to be launched into the market with an even lower
number of patients than we have today.' 3 We should note that the
FDA introduced a patent extension incentive for manufacturers
who conduct trials for pediatric indications.1 4 Having narrower,
more focused, and targeted populations, while an advantage in
reducing variation in response and reducing populations,
exacerbates the problem of sparse information at launch and of
specific sub-populations.
Interestingly, we are discovering, with the advent of molecular
level diagnostics and therapies, that minority populations are
frequently the patients who would benefit most from
individualized drug therapies. 15  There have been a number of
studies sponsored by the National Pharmaceutical Council
suggesting that, due to these individualized differences in response,
minorities need much broader access to medicines than might be
assumed. Using restrictive formularies and high co-pays to favor
one drug over another in the same therapeutic class rests on the
assumption of therapeutic substitution without any increase in
patient safety risk. The genomics revolution raises important
challenges to the assumption of fungibility among same-class
drugs. If the foundation of "managed care pharmacy" and price
negotiation with manufacturers is challenged by
pharmacogenomics, this too could be a barrier to adoption and
wide-spread commercialization. How do the incentives for health
plans, insurers, pharmaceutical benefit managers ("PBM's"), and
employers to manage pharmacy benefit costs reconcile with the
desirability and costs of individualized care?
At the clinical level, let's consider the package insert for
Strattera, a stimulant used to treat, among other conditions
attention deficit hyperactivity disorder ("ADHD") in children. 16
13. See, e.g., Andrew Pollack, DNA Chip May Help Usher in a New Era of
Product Testing, N.Y. Times, Nov. 28, 2000, at F2; Valentine J. Burroughs et
al., Cultural and Genetic Diversity in America: The Need for Individualized
Pharmaceutical Treatment, Nov. 2002, http://www.npcnow.org/resources/
PDFs/CulturalFINAL.pdf.
14. See generally Food and Drug Administration, The Pediatric Exclusivity
Provision: Status Report to Congress (2001), available at http://www.fda.gov/
cder/pediatric/reportcong01 .pdf.
15. Burroughs et al., supra note 13, at 13-14.
16. See Press Release, Eli Lilly and Company, Lilly Announces Important
Strattera® Label Update (Sept. 29, 2005), available at http://www.pmewswire
.com/micro/lly; Strattera.com, About Strattera, http://www.strattera.com/1 1
about strattera/_1 about.jsp (last visited Nov. 2, 2005).
2005]
LOUISIANA LA W REVIEW
The label gives the provider information about metabolism and the
enzymatic pathway. Clinicians have expressed concern about the
inadequacy of guidance in using these new data. 17  There are
typically very small population studies or non-existent clinical
information regarding dosage changes appropriate to guide
clinicians who would individualize therapy based on this additional
labeling. If clinicians cannot easily use the information, how will
its inclusion increase the value to clinicians and patients or the
reimbursers who share the payments for these medications? If
individualized therapy "fails" at the one-on-one interaction level
between doctor and patient, it is hard to see a market develop for
widespread use under the current circumstances. More clinical
guidance information will be needed. There are approximately
twenty prescription products on the market now with this kind of
labeling information included.18
So we find that there are barriers to the adoption of gene-based
diagnostics and therapies due to inadequate clinical information
and our current approaches to pharmacy management invite
physician skepticism about their relevance and necessity. Yet, if
we look at a historical example of a novel diagnostic we find that,
in spite of barriers, adoption increased and a market was
established.
The example I have in mind is the prostate specific antigen
("PSA") testing phenomenon, where testing for elevated PSA was
used to identify heightened susceptibility to, and diagnose, prostate
cancer. 19 Early on, there were many Type 2 errors with the
diagnostic; cost effectiveness studies were not available to suggest
that PSA diagnosis increased early identification, improved
outcomes and avoided disease-related costs. 20  But because of
17. Strattera product label information (the package insert) is available at
http://www.fda.gov/cder/foi/label/2002/2141 lstratteralbl.pdf.
18. See Center for Drug Evaluation & Research Report to the Nation,
Improving Public Health Through Human Drugs 17 (2002), available at
http://www.fda.gov/cder/reports/rtn/2002/Rtn2O02.PDF.
19. See American Cancer Society, Can Prostate Cancer Be Found Early?,
http://www.cancer.org/docroot/CRI/content/CRI_2_4_3X Can prostatecancer
be found early_36.asp (last visited Nov. 2, 2005); About.com, The Prostate-
Specific Antigen (PSA) Test Controversy, http://prostatecancer.about.com/od/
thepsacontroversy/i/issuep.htm (last visited Nov. 2, 2005); Yale-New Haven
Hospital, Diagnosing Prostate Cancer, http://www.ynhh.org/cancer/diagnosis/
prostate/diagnosis.html (last visited Nov. 2, 2005).
20.
Type 2 is refusing approval of a drug that is capable of saving many
lives or relieving great distress and that has no untoward side effects. If
you make a type 2 error, few will know it, as the people whose lives
might have been saved will not be around to protest, and their families
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wide-spread awareness of the existence of the test and poor
alternatives, the tests became more prevalent. 2 1 It suggests that if
there is sufficient concern by patients and physicians, if the
diagnostic or treatment fills in an existing void, if its specificity
and sensitivity may be somewhat flawed, then new innovations,
like individualized therapies, may take hold. The "proof' of cost-
effectiveness and the impact on overall quality of care will trail
behind as use increases.
The classic cost effectiveness measure is the cost of the new
strategy, minus the cost of the current method, divided by the
effect of the new strategy and effect of the current method.22 This
calculation is very sensitive to fatalities. The Warfarin and 6MP
examples are not typical; fatality is not a common outcome
associated with a drug-response related to variant alleles. Adverse
drug events from individual differences in drug response may
create costs but our current understanding suggests they rarely
result in death. Most of the work on pharmacogenomics and cost-
effectiveness has been done in the in-patient setting.23 We have
very little data and very little experience in understanding the fully
loaded costs of outpatient treatment failure. So making the case
for the cost-effectiveness of individualizing therapies will be just
that much more difficult in the out-patient setting, which is
relevant to many of the most widely used medicines and over-the-
counter (OTC) preparations. So again, it seems unlikely that for
the most widely used prescription medicines, a business case can
easily be made that individualizing therapy is going to reduce
health care costs. It suggests that the "value story" for
pharmacogenomics will be targeted to specific therapeutic areas,
sometimes for improved patient safety and in other cases for
improved patient outcomes and efficacy. In either case this may be
particularly challenging.
will have no way of knowing that their loved ones lost their lives
because of the caution of an unknown FDA official.
John Grohol, Food and Drug Administration, http://www.psychcentral.
com/psypsych/Food and DrugAdministration (last visited Nov. 2, 2005).
21. Robert G. Evans, Going for the Gold: The Redistributive Agenda
Behind Market-Based Health Care Reform, 22 J. Health Pol. Pol'y & L. 427,
461 & n.18 (1997).
22. M.F. Drummond et al., Users' Guides to the Medical Literature. XIII.
How to Use an Article on Economic Analysis of Clinical Practice. A. Are the
Results of the Study Valid? Evidence-Based Medicine Working Group, 277 J.
Am. Med. Ass'n. 1552-57.
23. David L. Veenstra et al., Assessing the Cost-Effectiveness of
Pharmacogenomics, AAPS Journal, Sept. 14, 2000, available at
http://www.aapspharmsci.org/view.asp?art=ps020329.
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Having noted these difficulties, there are cost-related
advantages to a widely-available diagnostic, such as one available
on the Internet as I described at the outset. These advantages can
be described in terms of cost avoidance and cost minimization.
For example, let us say that I have a variant allele that causes the
statin therapy I have been put on to be non-beneficial because I am
a "fast-metabolizer." My doctor and I may work on a regimen of
diet and exercise while increasing the dosage in the hopes of better
cholesterol numbers. Imagine that the genetic diagnostic allows
my doctor and me to quickly eliminate ineffective dosages and
whole therapy approaches. Those are costs avoided. These
advantages could also be extended to other therapeutic areas
beyond cholesterol testing if, let's say for example, I needed an
anti-depressant as well. There too, it is possible that my physician
and I could more quickly get my condition under control as a result
of the findings of a single diagnostic test. The possibility of taking
a test once at a single cost and being advantaged over the rest of
my lifetime, assuming the alleles at issue are not highly susceptible
to change from environmental exposures, is appealing and may,
over time, support a "cost avoidance" story to patients who pay
out-of-pocket or to reimbursers considering covering all or part of
the costs for the test.
One can also anticipate a treatment expansion effect, where
more patients might seek treatment because they are more
confident medicines will work for them. Similarly, practitioners
may more readily prescribe treatments because of increased
confidence in individualized therapy. While, at the surface,
treatment expansion would seem to be advantageous, for some
payers this is not necessarily in their self-interest. We have
experience with insurance coverage for smoking cessation, and
examples where specialized programs to identify and more
aggressivelY4 treat patients with statins were not continued or
reimbursed. Why? Because near-term costs increased and
avoidance of greater costs in the future were not likely to accrue to
the benefit of the current payer. Based on their experience,
patients were likely to opt-out of their health plan or employment
by the time the cost savings of greater investments in health today
would be realized tomorrow. Pharmacogenomics could face a
similar reaction where near-term increases in costs toward future
24. Statins are the class of cholesterol-lowering drugs, which stop the
enzymes they bind with from producing more cholesterol. Some nationalized
health care systems and commentators have questioned overuse. See Nick
Freemantle et al., The Use of Statins: A Case of Misleading Priorities?, 315 British
Med. J. 826 (1997).
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cost avoidance might be resisted for fear that some other payer will
realize the benefits, rather than the current third party payer.
It is very compelling, as a patient safety concern, that a
significant number of hospital admissions are due to adverse drug
events. 25 On the face of it, it makes you want to reach for the
promise of pharmacogenomics. But it is difficult to envision the
broad-scale implementation of pharmacogenomics for improving
patient safety. To illustrate this point, consider Propulsid
(cisapride), which was used to treat severe heartburn. 26 Propulsid
had a number of cardiovascular side effects.27 The FDA became
concerned enough to require 800,000 letters to go out to physicians
that relayed, "You need to know this. This needs to be handled
very carefully." However, those letters had little or no effect on
physician prescriptions. And what reason did the physicians give
for not responding to the letters and the rest of the precautions?
They said they already were overwhelmed with information, too
much so to focus on more data about one drug. So physician non-
responsiveness to pharmaceutical-specific risk information, even at
a population level, strikes me as a difficult challenge when
considered at the individual, personalized level.
Physician resistance or reluctance may prove to be a significant
barrier to adoption. To illustrate my point, consider an example
both Dr. Woodcock and I used earlier: testing for TPMT, an
enzyme that metabolizes 6MP, which is a drug used in childhood
cancer therapy. In response to this testing, physicians said, "I
already have other clinical markers that are easier and cheaper to
see." While this reaction caused the FDA to back away from a
requirement that the diagnostic be used before the onset of 6MP
therapy, it did not keep reimbursers from making this requirement.
It is my understanding that many insurers make their
reimbursement for 6MP contingent upon the diagnostic results. 28
This may be an example where a market mechanism such as
reimbursement is more efficient than a regulatory requirement to
gain compliance and improve patient safety.
25. Estimates vary regarding the incidence of adverse drug reactions in
different U.S. patient populations; there is some debate within the literature
regarding appropriate estimation techniques. See David Classen, Medication
Safety: Moving from Illusion to Reality, 289 J. Am. Med. Ass'n 1154 (2003).
26. Walter Smalley et al., Contraindicated Use of Cisapride: Impact of
Food and Drug Administration Regulatory Action, 284 J. Am. Med. Ass'n 3036
(2000).
27. Janssen Pharmaceutica Research Foundation, Dear Dr. Letter (June 26,
1998), http://www.fda.gov/medwatch/safety/1998/propul.htm.
28. Malorye Branca, The New, New Pharmacogenomics, BiolT, Sept. 9,
2002, http://www.bio-itworld.com/archive/090902/pharma.html.
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TPMT/6MP also raises the question of increased complexity
relating to gene-based therapies. If there are less complex
alternatives, as physicians claimed for 6MP adverse reactions, and
not a significant increase in patient risk, physicians may prefer
more familiar and less complex alternatives. The uptake of
pharmacogenomics will likely increase where these new data are
the only option to gain a significant increase in efficacy or patient
safety. Continuing along this line of complexity, there is the
phenomenon where, although you have a gene aberration, it does
not express itself phenotypically-a type of false positive. As a
practical matter, one can also question whether a particular assay
can be done quickly and relatively inexpensively. Also relevant is
whether the variant allele frequency is relatively high. In the wake
of an explosion of activity, we are finding many alleles that
represent small variances and appear with low frequency.
Throughout the field of genomics there is some concern that, if you
have too many discriminators, then the marker will not work in
commercial application. For commercialization and broad
adoption we must find the middle ground between too few and too
many genetic markers to create sub-populations that are adequately
sized.
Patient demand can push uptake. One of the factors that
increases demand is a significant recent change in the patient's or a
family member's health status. In other words, if I have just
received a diagnosis that moves me from "healthy," as self-
identified, to much less healthy, I am more risk-seeking and
willing to experiment with newer, less certain therapies. We can
also make the generalization that patients prefer relative certainty
to uncertainty. If patients were to seek out novel new treatment
options, they would be attracted to those that hold some promise of
improving their health status or improving their odds against
serious side effects. The more those "promises" are equivocal or
heavily weighted with uncertainty, the more they lose
attractiveness. We can extrapolate from these insights that a
unified "bundle" of strong association between the phenotype with
the variant allele, a reliable diagnostic, and an effective treatment
could create greater demand by patients for these newer therapies.
Price sensitivity also must be considered. Price sensitivity is a
function of health benefit, design, disposable income, and risk-
seeking disposition. It is interesting to me that for TPMT, $100-
$300 out-of-pocket was identified as a barrier given the severity of
[Vol. 66
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the consequences. 29 Of course these are direct expenses to the
patient, out-of-pocket, but nonetheless across a distribution of
patients from a distribution of disposable income levels this still
seems relatively low. The general principle we're seeing here is
that as gene-based therapies are available for targeted, smaller
populations, the cost of therapy must generally be higher because
the populations are smaller. For example, Herceptin, a treatment
for a very aggressive breast cancer associated with over-expression
of HER-2, is fifteen times the cost of the standard course of
therapy.3 ° We can expect that as you get smaller markets and
smaller numbers of patients, the therapy, and especially the
combination of the tailored therapy with associated diagnostic
prices, will be higher. Whether that creates any sensitivity
depends, in part, on whether the costs for diagnosis and treatment
are reimbursed and what the actual co-pays for patients are.
We should note that John Rowe, chairman and CEO of Aetna,
has publicly stated the advantages and importance of
pharmacogenomics, offering that Aetna encourages patients to
seek these diagnostics and treatments. 3 1 It would be interesting to
look carefully at the individual benefit designs of his company's
insurance products and those they administer for large employers.
Are they reimbursing for gene-based diagnostics and treatments
and the move toward individualized care? What is their experience
with patient costs and outcomes when they have access to these
new technologies? I strongly suspect that manufacturers who are
pursuing the commercialization of these products are working
closely with insurers to make these determinations and provide
support through benefit designs.
An additional concern, and potential barrier to
commercialization, that patients have expressed is confidentiality.
Information that one is more "difficult to treat," a conclusion that
could be drawn for some patients whose individual response to
some treatments is highly idiosyncratic, could prove to be a
liability to the patient. Patients may fear they will be labeled as a
29. Eliot Marshall, Preventing Toxicity with a Gene Test, 302 Science
Magazine 588, 590 (2003), available at http://www.sciencemag.org/cgi/
reprint/302/5645/ 588.pdf
30. Information about Herceptin is available at http://www.herceptin.com.
Herceptin generally is administered in combination with Taxol, and the total
cost of this cocktail is approximately £12,000 per patient for a six-month course
(£6,000 per drug). See Beezy Marsh, The Miracle Cocktail, Daily Mail, May
16, 2001, available at 2001 WLNR 2653507.
31. Associated Press, Genetic Testing Gets Backing from Aetna: Insurer
Asks Rivals to Back Anti-Bias Bill, Boston Globe, June 19, 2002, at C6 (quoting
Aetna Chief Executive Dr. John W. Rowe).
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result of test results regarding their individual drug response. In
partial response to this confidentiality concern, and to take the
burden off their own internal staff to provide complex customer
service, direct to consumer pharmacogenomic diagnostics results
go straight to the patient. Patients are encouraged to take their disc
to their doctor and confer with them. Can the doctor, under certain
circumstances, be required or unwittingly reveal that personalized
information about the patient to an insurer or employer? If patients
believe such a breach of confidentiality is possible, it could create
an additional barrier to their seeking more individualized
information. In addition, many doctors have suggested to me they
would be very concerned about that consultation. They simply
don't have the training and the paucity of well-controlled and
available data would make an interpretation of these results very
difficult.
Liability could be another barrier to broad adoption. Already,
there are issues associated with the commercial application of
pharmacogenomics that are the subject of litigation. For example,
a young boy, nine years old, suffered a Prozac-related death, and
variant alleles were subsequently identified as an explanation for
his adverse event.32 The case settled out of court.35 There was
also litigation against the former SmithKline regarding its Lyme
disease vaccine in which plaintiffs alleged that the manufacturer
should have a warning on its label about an arthritis side-effect
associated with patients with specific variant alleles.34 Another
company was sued because it preconditioned use of its drug on
screening for an allele associated with a granular cytosis side
effect.35 The basis for the suit was that the company was
inappropriately tying the diagnostic with the drug and thereby
artificially inflating the price of the therapy, so the company
moved away from linking distribution and sales of the drug with
the test.36 These cases illustrate that companies, which probably
have the best information about the clinical utility of coupling
pharmacogenomic diagnostics and drugs, may face not only
criticism but legal challenges and allegations of illegal tying
arrangements.
32. Stan Bernard, The 5 Myths of Pharmacogenomics, Pharmaceutical
Executive, Oct. 2003, at 7, available at http://www.pharmexec.com/pharm
exec/article/ articleDetail.jsp?id=72796.
33. Id.
34. Press Release, Mealey Publications, SmithKline Sued Over Lyme
Vaccine, available at http://www.whale.to/vaccines/lyme2.html (last visited
Nov. 2, 2005).
35. Bernard, supra note 32, at 74.
36. Noah, supra note 1, at 21.
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From the test supplier perspective, remember that there are
about a thousand commercial and home brew diagnostic tests. The
markets for each of these tests tend to be small, which has
discouraged some of the early innovators. With such small
markets, the unit price is likely to be higher, and that may create
greater price sensitivity depending on insurance coverage. For the
example I've used earlier, direct to consumer testing, the volume is
low. Orchid pharmaceuticals never came to market with its
predictive tests, even though people had invested a lot. Even so,
there is some competition in the field. Pay attention to Roche
Diagnostics and its partnership with Affymetrix for a p-450 chip
product to become commercially available. Many of the barriers
I've discussed will be confronted if this product comes to market
and we should learn a great deal from their marketing strategies. It
will be interesting to see if this draws new players into the market
and those that have delayed or withdrawn from the market.
Finally, from the perspective of the drug companies, there are
differing scenarios for the impact of pharamacogenomics on their
existing business models. Many drug executives have argued that
personalized medicine simply creates smaller markets and they,
therefore, are somewhat ambivalent about the impact of these new
therapies. 37  Yet, many of these same executives are
simultaneously making significant investments in alliances
acquisitions, and research in their own pharmacogenomics labs. 
3
The opportunity of the new sciences is leading somewhere, but it's
still too early to tell where. But a major company does not want to
be unaware of the application of the evolving science. One
attractive model is a market expansion model, often applied to
cancer therapies. Imagine that cancer therapy begins to look like
HIV treatment. Understanding the cancer(s) at the genetic level
allows the physician and patient to track it as it mutates. With
initial diagnosis, a patient receives a cocktail of drugs to attack the
current presentation of the disease. As that therapy becomes less
effective, a second diagnostic shows how the disease has mutated
and a new cocktail is prescribed. This model moves toward a more
chronic care model.
With all these commercialization challenges in mind, my own
judgment is that pharmacogenomics will most likely exacerbate the
current challenges we face in health care rather than solve them.
We are struggling, and many times failing, to practice the current
standard of care based on population-level understanding, much
less attempting to take the standard of care to a higher level of
37. Branca, supra note 28.
38. But cf. id.
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individualization. There are IOM studies, and others like the
RAND study published this past year in the New England Journal
of Medicine, that suggest we are having significant problems with
implementing appropriate use of basic medications in the context
of accepted clinical practice guidelines for widely recognized and
common conditions.39  If we can't meet expectations at the
population level, how can we expect to raise the standard even
higher toward individualized therapy? That, of course, is not to
say that individual doctors and their patients achieve a high level
of compliance to the best standards of care. Certainly there are
provider institutions that have made significant commitments and
have data to substantiate the significant progress they have made at
raising the quality of care. But my own data and interaction with
providers suggests it has been, and will continue to be, a
significant commitment of time and resources to achieve high-level
quality at the population level. It would be a significant challenge
for our best providers, as individuals and institutions, to raise the
level of care to that of so-called "personalized medicine."
39. Elizabeth A. McGlynn et al., The Quality of Health Care Delivered to
Adults in the United States, 348 New Eng. J. Med. 2635 (2003).
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